Surreal eye of surgeon examining cellular bladder landscape.

Second Look, Second Chance? How a Repeat TURBT Can Change the Game for Bladder Cancer

Samir D’Costa monogram
Samir D’Costa in Health & Wellness November 2026 • 3 min read.

"Could a second TURBT be a game-changer in predicting recurrence and progression in pT1HG bladder cancer? A single-center study says it's worth considering."


Bladder cancer is tricky. Initial diagnosis via transurethral resection (TURBT) can sometimes miss the full extent of the disease, a phenomenon known as understaging. This can lead to delays in getting the right treatment, especially for high-risk non-muscle-invasive bladder cancer (NMIBC).

So, what's the solution? A repeat TURBT, also known as re-cTURBT, comes into play. Studies show that re-cTURBT can reveal upstaging in a significant number of patients, meaning the cancer is more advanced than initially thought. In some cases, this upstaging rate can be as high as 49% when the first sample doesn't include muscle tissue.

A recent study investigated the value of re-cTURBT in patients with pT1HG (high-grade T1) bladder cancer. The goal was to determine if a second resection could help predict recurrence and progression by identifying residual tumors.

AI Search Multiple angles on this topic

Bladder Function and Health

The urinary bladder is a hollow, stretchy organ in the lower abdomen that stores urine until it leaves the body through the urethra. As the bladder fills, it signals the brain that it needs to be emptied; the surrounding muscles then contract while the sphincters relax to allow urination. Bladder conditions may cause problems with urination, although the provided sources do not establish specific statistics about bladder cancer or repeat TURBT.

Understanding Bladder Care

The provided source describes the bladder’s location, function, related conditions, healthy habits, and the types of clinicians who address bladder problems. It does not provide details about TURBT, repeat TURBT, accepted bladder-cancer treatment methods, or their limitations. Those procedure-specific questions therefore require sources focused directly on bladder cancer care.

A Foundation for Further Study

A historical account of bladder-cancer treatment and repeat TURBT would require evidence about surgical milestones, diagnostic discoveries, and changes in clinical practice. No such historical source material was provided here. Any timeline should therefore be developed from dedicated historical and urologic sources rather than inferred from general bladder anatomy.

Why a Second Look Matters: Re-cTURBT and Identifying Hidden Risks

Surreal eye of surgeon examining cellular bladder landscape.

The study, conducted at a single center, involved 285 patients who underwent TURBT for bladder cancer between January 2011 and December 2015. Among them, 92 patients were diagnosed with pT1HG. Following European Association of Urology (EAU) guidelines, these patients underwent a second TURBT (WLre-cTURBT) 4-6 weeks after the initial procedure.

After the second resection, researchers observed that:

  • A persistent disease was found in 18 (19.5%) patients.
  • 14 (15.2%) had high-grade NMIBC.
  • 4 (4.3%) were diagnosed with high-grade muscle-invasive bladder cancer (MIBC).
AI Search Multiple angles on this topic

Evidence Still Needed

Current research on repeat TURBT would normally be assessed through recent clinical studies, systematic reviews, and guideline updates. No research papers or reviews were supplied for this subsection. Conclusions about contemporary evidence, recurrence, staging, or outcomes should therefore be withheld until directly relevant sources are available.

Limits of the Available Evidence

A balanced discussion of repeat TURBT would need evidence about its drawbacks, unsuccessful procedures, complications, and arguments against repeating the operation. The provided material contains no such findings. It is therefore not possible to make a source-grounded comparison of benefits and failures here.

Comparisons Require Direct Evidence

Comparing repeat TURBT with other diagnostic or treatment approaches requires studies that evaluate those options using defined clinical outcomes. No comparative studies or procedure-specific sources were provided. The available general bladder information cannot support claims about which approach is more effective, safer, or preferable.

During the follow-up, recurrence was observed in 36 out of 92 patients (39.1%), and progression occurred in 14 patients (15.2%). The study also revealed that patients with persistent disease after re-cTURBT had a higher recurrence rate compared to those with no residual tumor (pT0).

The Takeaway: Re-cTURBT as a Valuable Tool

This research suggests that re-cTURBT is a valuable tool in managing high-risk NMIBC. By identifying persistent disease and accurately staging bladder cancer, re-cTURBT can help doctors make more informed decisions about treatment. The study highlights the need to consider re-cTURBT in patients with newly diagnosed, high-grade T1 bladder cancer.

AI Search Multiple angles on this topic

A Careful Clinical Perspective

The available material establishes only that the bladder stores urine and coordinates with the brain, muscles, sphincters, and urethra during urination. It does not include expert commentary on repeat TURBT or bladder-cancer decision-making. A clinically meaningful synthesis would require statements from qualified specialists and evidence focused on the procedure.

Future Questions

Future directions for repeat TURBT may involve improved diagnosis, treatment planning, and patient selection, but the provided sources do not discuss emerging technologies or research priorities. Specific predictions would therefore be speculative. A reliable outlook should draw on current trials, reviews, and expert guidance.

Context Beyond Anatomy

Bladder problems can affect urination, but the provided sources do not address healthcare access, diagnostic delays, treatment costs, or other systemic challenges related to bladder cancer. These broader issues cannot be established from general anatomy and function descriptions alone. Dedicated health-services and oncology sources would be needed for a supported discussion.

Living With Bladder Problems

Because the bladder stores urine and coordinates the process of emptying, bladder conditions may interfere with urination and daily life. The provided sources do not describe the lived experience of bladder-cancer patients, repeat TURBT, recovery, anxiety, or decision-making. Those human impacts should be addressed using patient-centered research or firsthand clinical and patient accounts.

How outcomes differed by repeat-resection result

  • 54.1 % of pT0 groupAmong the 48 patients whose repeat resection showed pT0 disease, 26 had recurrence: 54.1% of that group. This is a group-specific rate, not the rate for all patients in the study.[1]

Why residual disease mattered in this cohort

The main signal is the contrast between patients with persistent tumor and those whose repeat resection was negative: the groups did not share the same recurrence and progression experience. That makes the repeat-resection result a marker associated with later outcomes in this cohort, not proof that it predicts an individual patient’s course.[1]

The paper’s background notes that progression can still occur among patients with high-risk tumors treated with conventional resection and BCG. Its findings therefore sit within a clinical problem where risk remains, rather than showing that repeat resection prevents progression.[1]

Study at a glance
Study designObservational study[1]
Sample size92[1]
DurationAverage follow-up was 48 months[1]
Main outcomeRecurrence and progression following WLre-cTURBT[1]
Effect sizeRecurrence in 36/92 (39.1%) and progression in 14/92 (15.2%)[1]
p-valuep = 0.01[1]
Conflicts of interestNo conflict of interest declared[1]
Times cited7[1]

How this result fits with related work

An updated review of T1 patients treated with conventional TURBT in the 2010s estimated pooled rates for any residual tumor and upstaging; these metrics are not directly interchangeable with this single-center study’s outcome comparisons.[2]

Guideline material links absent detrusor muscle in the specimen with higher risks of residual disease, early recurrence, and understaging, offering a rationale for repeat assessment without establishing this study’s outcomes independently.[3]

A separate clinical statement says residual T1 disease at repeat resection is associated with subsequent progression risk approaching 80%; that estimate concerns a particular residual-disease subgroup and is not the cohort-wide rate here.[4]

What remains unresolved

  • Would the association between persistent disease and later outcomes hold in larger cohorts from multiple centers?[1]

Terms used in the study

pT0
No tumor identified after repeat resection.[1]

Sources

  1. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience (PAGEPress Publications, 2017)
  2. Repeat Transurethral Resection for Non-muscle-invasive Bladder Cancer: An Updated Systematic Review and Meta-analysis in the Contemporary Era. (pubmed.ncbi.nlm.nih.gov)
  3. Diagnosis - EAU Guidelines on Non-muscle-invasive Bladder Cancer - Uroweb (uroweb.org)
  4. www.auanet.org (www.auanet.org)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.4081/aiua.2017.4.272, Alternate LINK

Title: Can Re-Cturbt Be Useful In Pt1Hg Disease As A Risk Indicator Of Recurrence And Progression? A Single Centre Experience

Subject: Urology

Journal: Archivio Italiano di Urologia e Andrologia

Publisher: PAGEPress Publications

Authors: Roberto Giulianelli, Barbara Cristina Gentile, Gabriella Mirabile, Luca Albanesi, Paola Tariciotti, Giorgio Rizzo, Maurizio Buscarini, Mauro Vermiglio

Published: 2017-12-31

Everything You Need To Know

1

What is a TURBT, and why is it important in the context of bladder cancer?

TURBT, or transurethral resection, is a procedure used for the initial diagnosis and treatment of bladder cancer. It involves removing tumors from the bladder lining. However, it sometimes doesn't capture the full extent of the disease, leading to understaging. This is significant because inaccurate staging can result in inappropriate treatment strategies, especially for high-risk non-muscle-invasive bladder cancer (NMIBC). Understaging can lead to delays in administering the right treatment, potentially affecting patient outcomes. A more accurate assessment of the cancer's stage is critical for effective management.

2

What is a re-cTURBT, and why is it significant in managing bladder cancer?

Re-cTURBT, or repeat transurethral resection, is a second TURBT procedure performed after the initial one. It is important because it helps identify any remaining cancer cells or upstaging that the initial TURBT might have missed. This is especially crucial in high-risk NMIBC, where accurate staging is vital for effective treatment planning. Re-cTURBT helps in identifying persistent disease and ensures that the cancer is appropriately staged. In some instances, the upstaging rate can be significant, particularly when the initial TURBT sample did not include muscle tissue.

3

Who are pT1HG bladder cancer patients, and why were they the focus of this study?

The study focused on patients diagnosed with pT1HG bladder cancer, which refers to high-grade T1 tumors. This is significant because high-grade T1 bladder cancer carries a higher risk of recurrence and progression compared to lower-grade tumors. These patients often require more aggressive management strategies. The study aimed to evaluate if a second TURBT (re-cTURBT) could improve the prediction of recurrence and progression in this specific group by identifying any residual tumors that were not detected during the initial TURBT.

4

What are the European Association of Urology (EAU) guidelines, and why are they relevant to this discussion?

The European Association of Urology (EAU) guidelines recommend a second TURBT (re-cTURBT) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC), including those with pT1HG tumors. Following these guidelines ensures that patients receive the standard of care and that any residual tumors or upstaging are identified. Adhering to EAU guidelines is important as it helps standardize treatment approaches and improves patient outcomes by providing a framework for optimal management based on current evidence.

5

What were the key findings of the study regarding re-cTURBT and its impact on patient outcomes?

The study found that a persistent disease was present in 19.5% of patients after re-cTURBT. Additionally, 15.2% had high-grade NMIBC, and 4.3% were diagnosed with high-grade muscle-invasive bladder cancer (MIBC). These findings are significant because they demonstrate that re-cTURBT can reveal a considerable number of patients with residual disease or upstaging that was not detected in the initial TURBT. The study also revealed that patients with persistent disease after re-cTURBT had a higher recurrence rate compared to those with no residual tumor, emphasizing the value of re-cTURBT in predicting recurrence and progression.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.